While we are focused on XARELTO (RIVAROXABAN) cases that include deaths, we are also considering other XARELTO CASES involving blood transfusions, significant hospitalization or other serious side effects. Please contact us with any requests for information or a FREE CASE EVALUATION.
On June 14, 2012, REUTERS reported in “Insight: Top Heart Doctors Fret Over New Blood Thinners“, that cardiologist remain hesitant to prescribe the newest anti-coagulants. In part because there was little clinical knowledge of how they worked in application because they were so new. Additionally, concerns exist because there is no known antidote for these novel blood thinners. In other works, XARELTO (RIVAROXABAN) is not easily reversed, leaving a patient with blood that does not easily clot until the anti-coagulant literally wears off. This lack of antidote can lead to a fatal event or lengthy hospitalization.
These concerns continued to grow in Europe as reported byFiercePharma’s, Tracy Staton, in “Bayer’s Xarelto Faces Stepped Up Reports of Side Effects, Deaths“, where it was reported that Germanys’Der Speigel identified 968 side effect reports linked to XARELTO (RIVAROXABAN) including 72 XARELTO FATALITIES. These reports were published by Fierce Pharma on September 9, 2013.
Arguably, throughout 2014, safety “safety signals” and “red flags” have grown in the territorial United States. This is more fully explained in this post, which elaborates on the number of “safety signals” or potential “red flags” associated with a growing number of reports associated with the increased use of XARELTO (RIVAROXABAN).
Our investigations and the handling of a potential XARELTO CASE is on a contingency fee basis. These are no recovery – no fee contracts.